(Date:12/14/2009)... HOUSTON -- (Dec. 14, 2009) -- Researchers at Rice ... a single nanoparticle that can be tracked in real ... cells, tags them with a fluorescent dye and kills ... the first examples from a growing field called "theranostics" ... treat diseases in a single procedure. , The research ...
(Date:12/14/2009)... as a clean-burning, renewable fuel that could help wean ... caused by ozone, compared with gasoline, especially in winter, ... , Ozone production from both gasoline and E85, ... percent ethanol, is greater in warm sunny weather than ... because heat and sunlight contribute to ozone formation. But ...
(Date:12/14/2009)... Engineering Society (BMES) have founded a new journal ... CVET is a forum for research on ... The first issue of the new quarterly journal will ... publications at Springer, Annals of Biomedical Engineering ... Cardiovascular Engineering and Technology will present a wide ...
Breaking Biology News(10 mins):Tracking new cancer-killing particles with MRI 2Ethanol-powered vehicles generate more ozone than gas-powered ones 2Ethanol-powered vehicles generate more ozone than gas-powered ones 3Biomedical Engineering Society's new journal to be published by Springer 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 1Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 4Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 5Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 1Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 2Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 3Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 4Prospective Clinical Advantages of Trabecular Metal 28TM 29 Technology Highlighted in Comparative Study 4750 5Vein Condition May Mask Serious Clot Disorder 52152 1Vein Condition May Mask Serious Clot Disorder 52152 2... plants, human antibodies that could be used to treat ... 2005 American Society for Microbiology Biodefense Research Meeting. , ... is likely to strike at a time and place ... unpredictable nature of such events compels us to develop ...
... before they reach hospital, has the potential to save many ... over a million children die of malaria in Africa. The ... For those who do make it to hospital, half of ... given by injection, is not possible to administer outside hospital, ...
... of breast cancer,patients have an abnormality in a ... along that pathway may be,especially effective for treating ... Texas M. D. Anderson Cancer Center.", , A ... the phosphatidylinositol 3 kinase (PI3K),pathway to breast cancer ...
Other Biology News:Antibodies from plants protect against anthrax 2(Date:12/14/2009)... THOUSAND OAKS, Calif., Dec. 14 Array ... Inc.(Nasdaq: AMGN ) today announced that they ... rights to Array,s small-molecule glucokinase activator program, including ... clinical trial in patients with Type 2 diabetes. ... agreement, Array will receive an upfront payment of ...
(Date:12/14/2009)... The third edition of ... published by the Infusion Nurses Society (INS), ... extravasation.(1) Anthracyclines are a group of chemotherapy ... have been used in the treatment of various ... ,, According to the INS publication: "In ...
(Date:12/14/2009)... WALTHAM, Mass., Dec. 14 Decision Resources, ... firms for pharmaceutical and healthcare issues, finds that, ... the atrial fibrillation drug market will increase more ... $6.1 billion in 2018 in the United States, ... Japan. ,, The new Pharmacor report entitled ...
(Date:12/11/2009)... 11 Dendreon Corporation (Nasdaq: DNDN ... previously announced public offering have exercised in full ... of common stock at the public offering price ... the option increases the size of the offering ... stock. Dendreon expects to receive net proceeds ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5The Atrial Fibrillation Drug Market Will Increase More Than Sevenfold, from $790 Million in 2008 to $6.1 Billion in 2018 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3